His main concern, according to reports, is that Madrigal stock is expensive relative to its performance following a ...

In the high-stakes world of biotech investing, balancing risk and reward is everything. While clinical-stage Nektar Therapeutics (NKTR) shone in 2025 thanks to positive Phase 2 data for its ...

Nektar Therapeutics has a promising lead drug candidate, but there is considerable risk involved. Madrigal Pharmaceuticals is ...

Rezdiffra FDA approval fuels sales; expansion to F4 MASH cirrhosis with 2027 trial data. Read more about MDGL stock here.

Thankfully, 2026 could be a much better year for the Denmark-based drugmaker. Let's consider two tailwinds that could help ...

Madrigal’s Rezdiffra tops $1B run-rate in MASH, but losses and rising GLP-1/FGF21 competition may cap upside into 2026. See ...

Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Jan. 2, 2026 /CNW/ — Equity Insider News Commentary – The gene therapy market is surging toward $36.55 billion by ...

AstraZeneca's MFN pricing agreement with the US government reflects broader efforts to reduce drug prices and enhance ...

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.

CONSHOHOCKEN, Pa., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the J.P. Morgan Annual Healthcare Conference on ...

Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that the company's pipeline candidates will see strong progress in 2026. Novo ...